Gémes Katalin, Taipale Heidi, Björkenstam Emma, Rahman Syed, Gustafsson Klas, Tanskanen Antti, Ekselius Lisa, Mittendorfer-Rutz Ellenor, Helgesson Magnus
Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, Solna, Stockholm, Sweden.
Niuvanniemi Hospital, Kuopio, Finland.
Front Psychiatry. 2023 Apr 24;14:1152286. doi: 10.3389/fpsyt.2023.1152286. eCollection 2023.
Long-term medication use is a recommended treatment for attention-deficit/hyperactivity disorder (ADHD), however, discontinuation is common. Non-medical factors which might influence initiation and discontinuation are understudied. Therefore, we investigated how different sociodemographic factors and comorbidities were associated with the initiation and discontinuation of ADHD medication use among young adults.
We conducted a population-based prospective cohort study using individually linked administrative register data, in which we included all individuals residing in Sweden, between the age of 19 and 29 who were first diagnosed with ADHD between January 2006 and December 2016 ( = 59224). ADHD medication initiation was defined as the first prescription of ADHD medication in the period from 3 months before to 6 months after the cohort entry date. Those who initiated ADHD medication were followed up for medication use until discontinuation, death/emigration, or until 2019. Logistic and Cox regression models were used to investigate the associations between sociodemographics, health-related predictors and initiation, as well as discontinuation. Overall, 48.7% of the 41399 individuals initiated ADHD medication, most often methylphenidate (87%). Among the initiators, 15462 (77%) discontinued medication use during the follow-up (median time: 150 days). After mutually adjusting all other predictors, initiation was positively associated with older age, male sex, higher level of education, and negatively associated with living at home with parents, immigrant status, being unemployed during the year before inclusion, being on disability pension, having autism, substance use, schizophrenia-spectrum disorders, other mental disability/developmental disorders, cardiovascular diseases or previous accidents. Discontinuation was positively associated with being born abroad, living in big cities, being unemployed during the year before inclusion, having cancer, and negatively associated with a higher educational level, having depression, anxiety or stress-related disorder, autism spectrum disorder or diabetes.
Besides medical factors, sociodemographics, such as educational attainment and immigrant status might also play a role in the initiation and discontinuation of ADHD medication use among young adults newly diagnosed with ADHD.
长期药物治疗是注意力缺陷多动障碍(ADHD)的推荐治疗方法,然而,停药情况很常见。可能影响用药起始和停药的非医学因素研究不足。因此,我们调查了不同的社会人口统计学因素和合并症如何与年轻成年人ADHD药物治疗的起始和停药相关。
我们使用个体关联的行政登记数据进行了一项基于人群的前瞻性队列研究,纳入了2006年1月至2016年12月期间首次被诊断为ADHD的所有居住在瑞典的19至29岁个体(n = 59224)。ADHD药物治疗起始定义为队列进入日期前3个月至进入后6个月期间首次开具ADHD药物处方。对开始使用ADHD药物的患者进行随访,记录用药情况直至停药、死亡/移民或直至2019年。使用逻辑回归和Cox回归模型研究社会人口统计学、健康相关预测因素与用药起始以及停药之间的关联。总体而言,41399名个体中有48.7%开始使用ADHD药物,最常用的是哌甲酯(87%)。在开始用药者中,15462人(77%)在随访期间停药(中位时间:150天)。在对所有其他预测因素进行相互调整后,用药起始与年龄较大、男性、教育水平较高呈正相关,与与父母同住、移民身份、纳入研究前一年失业、领取残疾抚恤金、患有自闭症、药物使用、精神分裂症谱系障碍、其他精神残疾/发育障碍、心血管疾病或既往有事故呈负相关。停药与在国外出生、居住在大城市、纳入研究前一年失业、患有癌症呈正相关,与教育水平较高、患有抑郁症、焦虑或应激相关障碍、自闭症谱系障碍或糖尿病呈负相关。
除医学因素外,社会人口统计学因素,如教育程度和移民身份,也可能在新诊断为ADHD的年轻成年人ADHD药物治疗的起始和停药中起作用。